MannKind Corp. Share Price Today: Live Updates & Key Insights

MannKind Corp. share price today is $2.52, up -1.98%. The stock opened at $2.525 against the previous close of $2.52, with an intraday high of $2.525 and low of $2.41.

MannKind Corp. Share Price Chart

MannKind Corp.

us-stock
To Invest in {{usstockname}}
us-stock

MannKind Corp. Share Price Performance

$2.52 -0.0198(-1.98%) MNKD at 23 Mar 2026 02:18 PM Biotechnology
Lowest Today 2.41
Highest Today 2.525
Today’s Open 2.525
Prev. Close 2.52
52 Week High 6.51
52 Week Low 2.41
Day’s Range: Low 2.41 High 2.525
52-Week Range: Low 2.41 High 6.51
1 day return -
1 Week return -10.3
1 month return -55.47
3 month return -58.56
6 month return -55.43
1 year return -52.49
3 year return -37.21
5 year return -32.51
10 year return -

MannKind Corp. Institutional Holdings

BlackRock Inc 9.32

Vanguard Group Inc 5.80

State Street Corp 3.49

Vanguard Total Stock Mkt Idx Inv 2.97

State Street® SPDR® S&P® Biotech ETF 2.44

Rubric Capital Management LP 2.43

Geode Capital Management, LLC 2.39

iShares Russell 2000 ETF 2.39

Nitorum Capital, L.P. 1.73

UBS Group AG 1.69

venBio Select Advisor LLC 1.44

Dimensional Fund Advisors, Inc. 1.44

Frazier Life Sciences Management, L.P. 1.37

JPMorgan Chase & Co 1.33

Morgan Stanley - Brokerage Accounts 1.25

FMR Inc 1.16

Citadel Advisors Llc 1.16

Vanguard Institutional Extnd Mkt Idx Tr 1.08

Wellington Management Company LLP 1.07

Fidelity Select Biotechnology 1.07

Fidelity Small Cap Index 0.96

TSP Capital Management Group/LLC 0.96

180 WEALTH ADVISORS, LLC 0.96

Bank of America Corp 0.96

Northern Trust Corp 0.90

Charles Schwab Investment Management Inc 0.83

iShares Russell 2000 Growth ETF 0.82

iShares Biotechnology ETF 0.72

State St Russell Sm/Mid Cp® Indx SL Cl I 0.57

Fidelity Extended Market Index 0.52

Nuveen Quant Small Cap Equity R6 0.50

Schwab US Small-Cap ETF™ 0.48

Vanguard Russell 2000 ETF 0.47

Invesco Biotechnology & Genome ETF 0.46

DFA US Small Cap I 0.40

BlackRock Advantage Small Cap Core Instl 0.33

State St Russell Sm Cap® Indx SL Cl I 0.33

Dimensional US Small Cap ETF 0.32

Calamos Timpani Small Cap Growth I 0.29

Vanguard Health Care ETF 0.29

MannKind Corp. Market Status

Strong Buy: 6

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

MannKind Corp. Fundamentals

Market Cap 761.01 M

PB Ratio 187.8507

PE Ratio 123.5

Enterprise Value 957.10 M

Total Assets 792.18 M

Volume 19093757

MannKind Corp. Company Financials

Annual Revenue FY25:348966000 349.0M, FY23:176549000 176.5M, FY22:99770000 99.8M, FY21:75442000 75.4M, FY20:65144000 65.1M

Annual Profit FY25:287806000 287.8M, FY23:115721000 115.7M, FY22:42273000 42.3M, FY21:36585000 36.6M, FY20:40503000 40.5M

Annual Net worth FY25:5863000 5.9M, FY23:-31286000 -31.3M, FY22:-112169000 -112.2M, FY21:-91791000 -91.8M, FY20:-57240000 -57.2M

Quarterly Revenue Q4/2025:111955000 112.0M, Q3/2025:82130000 82.1M, Q2/2025:76527000 76.5M, Q1/2025:78354000 78.4M, Q3/2024:70079000 70.1M

Quarterly Profit Q4/2025:87834000 87.8M, Q3/2025:61927000 61.9M, Q2/2025:55959000 56.0M, Q1/2025:60838000 60.8M, Q3/2024:52056000 52.1M

Quarterly Net worth Q4/2025:-15948000 -15.9M, Q3/2025:7985000 8.0M, Q2/2025:668000 0.7M, Q1/2025:13158000 13.2M, Q3/2024:11550000 11.6M

About MannKind Corp. & investment objective

Company Information MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Organisation Biotechnology

Employees 591

Industry Biotechnology

CEO Dr. Michael E. Castagna Pharm.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

MannKind Corp. FAQs

What is the share price of MannKind Corp. today?

The current share price of MannKind Corp. is $2.52.

Can I buy MannKind Corp. shares in India?

Yes, Indian investors can buy MannKind Corp. shares by opening an international trading and demat account with Motilal Oswal.

How to buy MannKind Corp. shares in India?

You can easily invest in MannKind Corp. shares from India by:

Can I buy fractional shares of MannKind Corp.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of MannKind Corp.?

MannKind Corp. has a market cap of $761.01 M.

In which sector does MannKind Corp. belong?

MannKind Corp. operates in the Biotechnology sector.

What documents are required to invest in MannKind Corp. stocks?

To invest, you typically need:

What is the PE and PB ratio of MannKind Corp.?

The PE ratio of MannKind Corp. is 123.50 and the PB ratio is 187.85.